NCT05396781View on ClinicalTrials.gov

Acceptability and Performance of a Mobile Optical Biopsy Technology for Gastrointestinal Cancer Screening

PHASE2CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 13, 2022

Primary Completion Date

January 20, 2022

Study Completion Date

January 20, 2022

Conditions
Suspected or Known Squamous Cell NeoplasiaPrior History of Squamous Cell Dysplasia and /or Neoplasia
Interventions
DRUG

Proflavine

5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa.

DEVICE

Mobile, Augmented High Resolution Microendoscope

The marHRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.

Trial Locations (2)

77030

Baylor College of Medicine, Houston

01246-000

University of Sao Paulo, São Paulo

All Listed Sponsors
collaborator

William Marsh Rice University

OTHER

collaborator

Baylor College of Medicine

OTHER

collaborator

University of Sao Paulo

OTHER

lead

Anandasabapathy, Sharmila, M.D.

INDIV